Dennis C. Mays

TL;DR: In patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine, 6-thioguanine nucleotide concentrations did not correlate with disease activity, as measured by theinflammatory bowel disease questionnaire, or leucocyte count.

TL;DR: A loading dose does not decrease the time to response in patients with steroid-treated Crohn's disease beginning azathioprine therapy, and steady state of erythrocyte 6-thioguanine nucleotide and complete response occurred earlier than previously reported.

TL;DR: It is demonstrated that mesalamine, an anti-inflammatory aminosalicylate, dose-dependently inhibits IL-1-stimulated NF-κB-dependent transcription without preventing IκB degradation or nuclear translocation and DNA binding of the transcriptionally active NF- κB proteins, RelA, c-Rel, or RelB.

TL;DR: In patients with Crohn's disease receiving azathioprine or 6-mercaptopurine, coadministration of mesalamine, sulphasalazine, and possibly balsalazide results in an increase in whole blood 6-thioguanine nucleotide concentrations and a high frequency of leucopenia.

TL;DR: An 1800-mg intravenous loading dose of azathioprine is safe and may decrease the time to response to < or = 4 weeks in patients with Crohn's disease.